A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 180
Summary
- Conditions
- Age - Related Macular Degeneration
- Neovascular Age Related Macular Degeneration
- Wet Macular Degeneration
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 50 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03834753
- Collaborators
- Not Provided
- Investigators
- Study Director: Jennifer M Kissner, PhD Outlook Therapeutics, Inc.
Get Well Soon